Clinical Trial Update: Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases [Phase 1]

View source ↗

Summary

Phase 1 open-label trial investigating [11C]Osimertinib in EGFR-mutant NSCLC with brain metastases; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• [11C]Osimertinib (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non-small Cell Lung Cancer | Phase 1 | Status: COMPLETED | Results posted: 2023-01-27